HHS Will Take Anti-Kickback Safe Harbor Proposals For Drug Contracting ‘Seriously,’ US Official Promises
Executive Summary
Health and Human Services Department Deputy Secretary Eric Hargan invites biopharma companies to submit proposals on how to modify or create safe harbors that would be suitable for innovative reimbursement contracts involving prescription drugs.
You may also be interested in...
OIG Still Wary Of Anti-Kickback Safe Harbors For Value-Based Arrangements Involving Drugs
US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.
HHS Safe Harbor For Value-Based Drug Contracts May Be On Horizon
US proposed rule establishing new safe harbors from anti-kickback rules for value-based and outcomes-based contracts limits protections to clinicians, providers and certain other groups and expressly excludes pharmaceutical manufacturers. But HHS suggests a separate safe harbor for prescription drug contracts may be forthcoming.
Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.